Kyocera and Tokyo Medical Dental University Develop Cardiac Rehabilitation Therapy Employing Vuzix Blade Smart Glasses

News provided by

Dec 01, 2022, 10:32 ET

ROCHESTER, N.Y., Dec. 1, 2022 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced that Kyocera, a Japanese multinational supplier technology and healthcare products and components, has developed a cardiac rehabilitation treatment in collaboration with Tokyo Medical Dental University (TMDU) that employs Vuzix Blade® smart glasses.

Kyocera headset with bio-sensing function, Vuzix Blade Smart Glasses and a small electrocardiograph

The system, developed in collaboration with Tomoyuki Umemoto (MD, PhD) and his colleagues in the Department of Cardiovascular Medicine at Tokyo Medical and Dental University (TMDU), combines a Kyocera bone conduction headset with biometric sensing, Vuzix Blade smart glasses, and a small electrocardiograph (ECG). Patients undergoing cardiac rehabilitation therapy wear the headset and ECG, while physicians wear the smart glasses to monitor the biometric data. Abnormalities in pulse, oxygen saturation, and ECG can be detected visually and audibly, allowing the therapist to assist the patient with both hands free. Customized software displays various biological information on the smart glasses so that it can be grasped in an integrated manner.

By utilizing this system, physicians can acquire and view vital data such as pulse rate, oxygen saturation, and ECG in real time during exercise while talking with patients undergoing cardiac rehabilitation therapy. This enables guidance on the amount of exercise to be performed, which is expected to lead to more accurate diagnosis and shorter treatment time. The evaluation trial currently underway aims to verify the effectiveness of this system for telemedicine and remote rehabilitation, and if it can also be applied to other diseases, ultimately aiming for full-scale introduction in the future.

This system has also been applied to COVID-19. Currently, rehabilitation therapy is provided by direct intervention for severely ill patients, and remotely for moderately ill patients who have recovered to independent walking. By introducing tele-rehabilitation, the center aims to achieve early recovery of patients, reduce the risk of infection for medical staff, and conserve medical resources such as protective clothing and masks.

"Vuzix Blade smart glasses are lightweight, comfortable and completely wireless. They're the ideal form factor for ongoing patient-therapist interaction such as occurs with this rehabilitation system," said Paul Travers, President and Chief Executive Officer at Vuzix. "We are pleased to keep expanding our engagement opportunities within the healthcare vertical and look forward to increasing deployment opportunities across multiple applications and geographies."

About Vuzix Corporation

Vuzix is a leading supplier of Smart Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. The Company's products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality. Vuzix holds 259 patents and patents pending and numerous IP licenses in the Video Eyewear field. Moviynt, an SAP Certified ERP SaaS logistics solution provider, is a Vuzix wholly owned subsidiary. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2023 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in Rochester, NY, Oxford, UK, and Tokyo, Japan. For more information, visit the Vuzix website, Twitter and Facebook pages.

Forward-Looking Statements Disclaimer

Certain statements contained in this news release are "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward looking statements contained in this release relate to Vuzix Smart Glasses, our business relationship and future opportunities with Tokyo Medical Dental University and Kyocera and its customers, and among other things the Company's leadership in the Smart Glasses and AR display industry. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Vuzix Media and Investor Relations Contact:

Ed McGregor, Director of Investor Relations,
Vuzix Corporation
[email protected]
Tel: (585) 359-5985

Vuzix Corporation, 25 Hendrix Road, West Henrietta, NY 14586 USA,
Investor Information – [email protected] www.vuzix.com

SOURCE Vuzix Corporation